What's in Centre for Addiction and Mental Health's pipeline?

Centre for Addiction and Mental Health has 18 drugs in our index: 12 marketed, 0 filed, 0 in Phase 3, 2 in Phase 2, 4 in Phase 1.

Which companies overlap with Centre for Addiction and Mental Health's portfolio?

Top competitors by shared drug class: , Eldon Loh, MD, Fougera, Massachusetts General Hospital, NEMA Research, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/centre-for-addiction-and-mental-health.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Centre for Addiction and Mental Health — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Centre for Addiction and Mental Health pipeline: 12 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

12 marketed 0 filed 0 Phase 3 2 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Tobacco	Tobacco	marketed	Nitrate Vasodilator [EPC]		Other
Nicotine Replacement Therapy Agent	Nicotine Replacement Therapy Agent	marketed
Bupropion Augmentation	Bupropion Augmentation	marketed
Apo-Oxycodone CR®	Apo-Oxycodone CR®	marketed
Placebo plus clinical management	Placebo plus clinical management	marketed			Psychiatry/Addiction Medicine
OxyNEO®	OxyNEO®	marketed	Opioid analgesic, abuse-deterrent formulation	Mu-opioid receptor	Pain Management
Switch to bupropion	Switch to bupropion	marketed	Norepinephrine-dopamine reuptake inhibitor (NDRI)	Norepinephrine transporter (NET); Dopamine transporter (DAT)	Psychiatry / Mental Health
Switch to nortriptyline	Switch to nortriptyline	marketed	Tricyclic antidepressant (TCA)	Norepinephrine transporter (NET), serotonin transporter (SERT)	Psychiatry / Mental Health
Nabilone Oral Capsule	Nabilone Oral Capsule	marketed	Synthetic cannabinoid	CB1 and CB2 cannabinoid receptors	Oncology; Pain Management; Psychiatry
Lithium Augmentation	Lithium Augmentation	marketed	Mood stabilizer / Augmentation agent	Inositol monophosphatase; protein kinase C; glycogen synthase kinase-3 (GSK-3)	Psychiatry / Mental Health
Dexedrine	Dexedrine	marketed			Other
Aripiprazole Augmentation	Aripiprazole Augmentation	marketed	Atypical antipsychotic / dopamine partial agonist	D2 dopamine receptor, 5-HT1A serotonin receptor	Psychiatry / Mental Health

Therapeutic area mix

Psychiatry / Mental Health · 4
Other · 3
Oncology; Pain Management; Psychiatry · 1
Pain Management · 1
Psychiatry · 1
Psychiatry/Addiction Medicine · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
Eldon Loh, MD · 1 shared drug class
Fougera · 1 shared drug class
Massachusetts General Hospital · 1 shared drug class
NEMA Research, Inc. · 1 shared drug class
National Institute of Mental Health (NIMH) · 1 shared drug class
New York State Psychiatric Institute · 1 shared drug class
Novartis · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Centre for Addiction and Mental Health:

Cite this brief

Drug Landscape (2026). Centre for Addiction and Mental Health — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centre-for-addiction-and-mental-health. Accessed 2026-05-17.